Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. more
Time Frame | OCS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.35% | 2.44% | 2.58% |
1-Month Return | 11.06% | -4.49% | 0.09% |
3-Month Return | 40.84% | -8.82% | 4.76% |
6-Month Return | 44.05% | -4.46% | 9.89% |
1-Year Return | 55.18% | 3.16% | 26.47% |
3-Year Return | 75.98% | -0.83% | 25.98% |
5-Year Return | 75.98% | 35.65% | 86.34% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | 993.00K | 960.00K | 912.00K | 883.00K | [{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.68,"profit":true},{"date":"2022-12-31","value":91.84,"profit":true},{"date":"2023-12-31","value":88.92,"profit":true}] | |
Cost of Revenue | 9.34M | 9.57M | 22.22M | 29.25M | [{"date":"2020-12-31","value":31.92,"profit":true},{"date":"2021-12-31","value":32.71,"profit":true},{"date":"2022-12-31","value":75.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Gross Profit | (8.34M) | (8.61M) | (21.31M) | (28.36M) | [{"date":"2020-12-31","value":-834400000,"profit":false},{"date":"2021-12-31","value":-860800000,"profit":false},{"date":"2022-12-31","value":-2131200000,"profit":false},{"date":"2023-12-31","value":-2836400000,"profit":false}] | |
Gross Margin | (840.28%) | (896.67%) | (2336.84%) | (3212.23%) | [{"date":"2020-12-31","value":-840.28,"profit":false},{"date":"2021-12-31","value":-896.67,"profit":false},{"date":"2022-12-31","value":-2336.84,"profit":false},{"date":"2023-12-31","value":-3212.23,"profit":false}] | |
Operating Expenses | 12.34M | 13.23M | 32.38M | 52.35M | [{"date":"2020-12-31","value":23.56,"profit":true},{"date":"2021-12-31","value":25.28,"profit":true},{"date":"2022-12-31","value":61.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (12.34M) | (13.23M) | (32.38M) | (80.71M) | [{"date":"2020-12-31","value":-1233600000,"profit":false},{"date":"2021-12-31","value":-1323200000,"profit":false},{"date":"2022-12-31","value":-3237600000,"profit":false},{"date":"2023-12-31","value":-8071400000,"profit":false}] | |
Total Non-Operating Income/Expense | (5.07M) | (10.39M) | (12.58M) | (7.87M) | [{"date":"2020-12-31","value":-507200000,"profit":false},{"date":"2021-12-31","value":-1039200000,"profit":false},{"date":"2022-12-31","value":-1258300000,"profit":false},{"date":"2023-12-31","value":-786700000,"profit":false}] | |
Pre-Tax Income | (14.79M) | (18.52M) | (38.64M) | (88.69M) | [{"date":"2020-12-31","value":-1479000000,"profit":false},{"date":"2021-12-31","value":-1852400000,"profit":false},{"date":"2022-12-31","value":-3864300000,"profit":false},{"date":"2023-12-31","value":-8869500000,"profit":false}] | |
Income Taxes | 83.00K | 27.00K | 55.00K | 107.00K | [{"date":"2020-12-31","value":77.57,"profit":true},{"date":"2021-12-31","value":25.23,"profit":true},{"date":"2022-12-31","value":51.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Income After Taxes | (14.87M) | (18.55M) | (38.70M) | (88.80M) | [{"date":"2020-12-31","value":-1487300000,"profit":false},{"date":"2021-12-31","value":-1855100000,"profit":false},{"date":"2022-12-31","value":-3869800000,"profit":false},{"date":"2023-12-31","value":-8880200000,"profit":false}] | |
Income From Continuous Operations | (14.87M) | (18.55M) | (38.70M) | (88.80M) | [{"date":"2020-12-31","value":-1487300000,"profit":false},{"date":"2021-12-31","value":-1855100000,"profit":false},{"date":"2022-12-31","value":-3869800000,"profit":false},{"date":"2023-12-31","value":-8880200000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (14.87M) | (18.55M) | (38.70M) | (88.80M) | [{"date":"2020-12-31","value":-1487300000,"profit":false},{"date":"2021-12-31","value":-1855200000,"profit":false},{"date":"2022-12-31","value":-3869800000,"profit":false},{"date":"2023-12-31","value":-8880200000,"profit":false}] | |
EPS (Diluted) | - | 0.10 | 0.04 | (2.71) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":40,"profit":true},{"date":"2023-12-31","value":-2710,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
OCS | |
---|---|
Cash Ratio | 3.81 |
Current Ratio | 4.02 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
OCS | |
---|---|
ROA (LTM) | -33.46% |
ROE (LTM) | -69.33% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
OCS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.24 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.76 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
OCS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 813.05 |
P/B | 6.66 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Oculis Holding AG Ordinary shares (OCS) share price today is $17.07
Yes, Indians can buy shares of Oculis Holding AG Ordinary shares (OCS) on Vested. To buy Oculis Holding AG Ordinary shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in OCS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Oculis Holding AG Ordinary shares (OCS) via the Vested app. You can start investing in Oculis Holding AG Ordinary shares (OCS) with a minimum investment of $1.
You can invest in shares of Oculis Holding AG Ordinary shares (OCS) via Vested in three simple steps:
The 52-week high price of Oculis Holding AG Ordinary shares (OCS) is $18. The 52-week low price of Oculis Holding AG Ordinary shares (OCS) is $10.11.
The price-to-earnings (P/E) ratio of Oculis Holding AG Ordinary shares (OCS) is
The price-to-book (P/B) ratio of Oculis Holding AG Ordinary shares (OCS) is 6.66
The dividend yield of Oculis Holding AG Ordinary shares (OCS) is 0.00%
The market capitalization of Oculis Holding AG Ordinary shares (OCS) is $705.72M
The stock symbol (or ticker) of Oculis Holding AG Ordinary shares is OCS